单剂量西普罗夫洛克萨与12剂量红色素治疗儿童霍乱:一项随机对照试验
Debasish Saha1, Wasif A Khan, Mohammad M Karim
1ICDDR, B, Centre for Health and Population Research, Dhaka, Bangladesh. dsaha@icddrb.org
Lancet (London, England)
|September 27, 2005
概括
与红红素相比,单剂量西普罗夫洛克萨在严重的儿童霍乱中提供了类似的临床治愈率. 然而,西普洛素在从便样本中根除Vibrio cholerae细菌方面效果不佳.
科学领域:
- 儿童传染病 儿童传染病
- 抗菌疗法是一种抗菌疗法.
- 胃肠病学 胃肠病学
背景情况:
- 在儿童中严重的霍乱需要有效的治疗.
- 齐普罗夫洛克萨是一种潜在的单剂量选择,用于治疗霍乱.
研究的目的:
- 为了比较单剂量西普罗夫洛克萨与多剂量红色素在治疗儿童严重霍乱的疗效.
- 评估临床治愈率和细菌根除.
主要方法:
- 一个随机的,开放的标签试验,涉及2-15岁的儿童,患有严重霍乱.
- 参与者在3天内接受单剂量西普罗夫洛克萨或12剂量红色素.
- 临床成功被定义为48小时内停止水性便.
主要成果:
- 临床成功率相似:西普罗夫洛克萨的60%和红色素的55%.
- 齐普罗夫洛克萨组的吐减少,便减少,便量减少.
- 与红红素 (30%) 相比,西普罗夫洛克萨 (58%) 的细菌性衰竭明显高于红红素 (30%).
结论:
- 单剂量西普罗夫洛克萨的临床结果与多剂量红色素治疗儿童霍乱的临床结果相似.
- 红素在消灭Vibrio cholerae方面表现出卓越的疗效.
- 可能需要进一步的研究来优化西普罗夫洛克萨的使用或探索细菌清除的替代方案.
相关概念视频
Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...

